- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
July 5th, 2010
With last week's announcement that Patrick Soon-Shiong is selling Abraxis BioScience Inc. for $2.9 billion, the biotech entrepreneur won't have a company to run for the first time in more than two decades.
But there's one thing the billionaire will have: more money, more liquidity and more time to pursue his philanthropy, as well as possible side ventures.
Meanwhile, Soon-Shiong made it clear he is not abandoning all his business interests.
He was the inventor of the nanotechnology that has made Abraxis a success in treating late-stage breast cancer. His agreement with Celgene gives him a consulting role in the attempt to expand Abraxane's market to other cancers, including of the skin, lung and pancreas.
|Related News Press|
News and information
Graphenea celebrates fifth anniversary April 27th, 2015
Arrowhead to Report Fiscal 2015 First Quarter Financial Results February 2nd, 2015
Graphenea sales more than double in 2014 January 29th, 2015